Skip to main content
. Author manuscript; available in PMC: 2015 May 15.
Published in final edited form as: J Immunol. 2014 Apr 9;192(10):4748–4757. doi: 10.4049/jimmunol.1303190

Figure 3. Downregulation of anxA2 reduces uptake of HPV16L1L2 VLP.

Figure 3

A. LC were transfected without siRNA (untreated), with control siRNA or an anti-anxA2 siRNA SMARTpool. The cells were incubated for 5 days before analysis of anxA2 protein expression by Western blot. Beta-actin served as the loading control. One representative experiment of four is shown. B. LC were transfected without siRNA (untreated), with Non-Target siRNA or with an anti-anxA2 siRNA SMARTpool. The cells were incubated for 5 days and exposed to CFDA-SE labeled HPV16 L1L2 VLP, or HPV16 L2 mutant VLP for 45 min. Uptake was assessed by flow cytometry normalized to untreated LC. These data are representative examples of three experiments performed in triplicate shown as the mean ± SD (**P < 0.01 as determined by a two-tailed, unpaired t-test, as compared to untreated LC)